Study detail
RecruitingPhase 1
A Phase 1, Open-Label Study of ABSK-011 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumors
Abbisko Therapeutics Co, Ltd
Summary
This is an open-label phase 1 study with an escalation part and an expansion part.
Description
The escalation part will evaluate the safety, tolerability, PK and recommended dose of expansion (RDE) of oral ABSK-011 in patients with advanced solid tumors. The expansion part of oral ABSK-011 at RDE will be followed for further evaluating safety and tolerability in patients with FGF19 overexpression advanced HCC. Preliminary antitumor activity will also be assessed.
Eligibility
- Age range
- 18–75 years
- Sex
- All
- Healthy volunteers
- No